Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Closed

Phase

Abbreviated Title

Status Notes

This study reactivated to accrual 7/15/20.

Activated

08/18/2014

Closed

01/20/2021

Participants

CTSU

Research committees

Lung Cancer

Treatment

Erlotinib

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number

A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)

Research Committee(s)

Lung Cancer

Activated

03/02/2027

Open

SWOG Clinical Trial Number

S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Research Committee(s)

Lung Cancer

Activated

09/08/2025

Accrual

Open

Phase

SWOG Clinical Trial Number

CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)

Research Committee(s)

Lung Cancer

Activated

06/13/2025

Open

Phase